Sensulin

Sensulin is a preclinical biopharmaceutical company, that is developing a glucose-responsive insulin for type 1 and type 2 diabetes. Sensulin aims to substantially lower the risk of hypoglycemia, reduce the long-term complications associated with diabetes (eye & kidney disease, etc.), while reducing the number of required daily injections. Ultimately, Sensulin may eliminate the need for separate basal & mealtime insulin, offer a substantial improvement in the standard care, and most importantly, give those with diabetes a chance at a normal life.